Dermatology, MOHS-Micrographic Surgery · Davenport, FL
NPI
1669449047
Since 2006
Specialty
Dermatology, MOHS-Micrographic Surgery
Code 207ND0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2502 Sand Mine Rd
Davenport, FL, 33897
Phone (855) 353-7546
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
8,422 services
Medicare patients, 2024
1,318
Average age 78
Drug cost, 2024
$501K
5,341 prescriptions
Company payments, 2025
$15.26
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by K W Foster was code 88332 (surgical pathology examination), 2,966 times for 251 patients. In total K W Foster billed 8,422 services in 82 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-04-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 88332 Surgical Pathology Examination | Office | 2,966 | 251 | $44.58 | $132K |
| 17311 Mohs Surgery | Office | 744 | 566 | $459.36 | $342K |
| 88305 Surgical Pathology Examination | Office | 546 | 358 | $27.23 | $15K |
| 13121 Wound Repair - All Levels | Office | 444 | 363 | $256.09 | $114K |
| 13132 Wound Repair - All Levels | Office | 370 | 317 | $209.21 | $77K |
| 88331 Surgical Pathology Examination | Office | 370 | 261 | $82.71 | $31K |
| 11602 Skin Lesion Excision | Office | 314 | 234 | $101.52 | $32K |
| 17312 Mohs Surgery | Office | 279 | 182 | $339.87 | $95K |
| 11103 Skin Biopsy | Office | 260 | 102 | $41.47 | $11K |
| 17003 Destruction Skin Lesion | Office | 249 | 51 | $5.28 | $1,314 |
| 11102 Skin Biopsy | Office | 239 | 198 | $56.42 | $13K |
| 17313 Mohs Surgery | Office | 238 | 187 | $458.37 | $109K |
| 13101 Wound Repair - All Levels | Office | 215 | 190 | $280.57 | $60K |
| 99213 Office E&M - Established | Office | 145 | 114 | $67.50 | $9,788 |
| 17000 Destruction Skin Lesion | Office | 93 | 84 | $31.34 | $2,915 |
By year: 2022 $1.1M for 6,891 services; 2023 $1.2M for 7,554 services; 2024 $1.3M for 8,422 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88332 Surgical Pathology Examination | 2,966 | 251 | $44.58 | $132K |
| 88305 Surgical Pathology Examination | 546 | 358 | $27.23 | $15K |
| 88331 Surgical Pathology Examination | 370 | 261 | $82.71 | $31K |
Medicare prescription drug claims, 2024
In 2024, the drug K W Foster prescribed most often to Medicare patients was Clindamycin Hcl, with 2,688 prescriptions and refills. In total K W Foster wrote 5,341 Medicare prescriptions that cost $501K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clindamycin Hcl Generic | 2,688 | 2,690 | 1,918 | $13K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 1,330 | 1,330 | 1,077 | $2,686 |
| Doxycycline Hyclate Generic | 683 | 684 | 518 | $4,441 |
| Triamcinolone Acetonide Generic | 82 | 93 | 69 | $1,295 |
| Ssd Silver Sulfadiazine | 66 | 69 | 62 | $562 |
| Fluorouracil Generic | 62 | 63 | 56 | $4,844 |
| Cephalexin Generic | 51 | 51 | 47 | $255 |
| Mupirocin Generic | 33 | 33 | 27 | $223 |
| Silver Sulfadiazine Generic | 31 | 32 | 23 | $250 |
| Tramadol Hcl Generic | 29 | 29 | 25 | $35.97 |
| Hydrocortisone Generic | 28 | 28 | 26 | $164 |
| Erivedge Vismodegib | 21 | 21 | Under 11 | $272K |
| Hydroxyzine Hcl Generic | 19 | 27 | Under 11 | $187 |
| Ciprofloxacin Hcl Generic | 19 | 19 | 13 | $64.56 |
| Erythromycin Erythromycin Base | 17 | 17 | 15 | $183 |
Brand drugs: 134 claims; generic drugs: 5,207 claims; opioid claims: 1,361.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid K W Foster $15.26 ($15.26 in general payments such as food, travel and fees) from 1 company. The largest payer was Amgen Inc. with $15.26.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 1 | $15.26 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.